Purpose:To investigate the comparison between diffusion-weighted imaging ͑DWI͒, T 2 -weighted imaging, ͑T 2 WI͒ and contrast T 1 -weighted imaging ͑cT 1 WI͒ in uterine leiomyoma following treatment by magnetic resonance imaging-guided, high intensity focused ultrasound surgery ͑MRg-HIFUS͒. Methods: Twenty one patients ͑45Ϯ 5 yrs͒ with clinical symptoms of uterine leiomyoma ͑fibroids͒ were treated by MRg-HIFUS using an integrated 1.5T MRI-HIFUS system. MRI parameters consisted of DWI, T 2 WI, and T 1 -weighted fast spoiled gradient echo before and after contrast. The post-MRg-HIFUS treatment volume in the fibroid was assessed by cT 1 WI and DWI. Trace apparent diffusion coefficient maps were constructed for quantitative analysis. The regions of the treated uterine tissue were defined by a semisupervised segmentation method called the "eigenimage filter," using both cT 1 WI and DWI. Signal-to-noise ratios were determined for the T 2 WI pretreatment images. Segmented regions were tested by a similarity index for congruence. Descriptive, regression, and Bland-Altman statistics were calculated. Results: All the patients exhibited heterogeneously increased DWI signal intensity localized in the treated fibroid regions and were colocalized with the cT 1 WI defined area. The mean pretreatment T 2 WI signal intensity ratios were T 2 WI/ muscle= 1.8Ϯ 0.7 and T 2 WI/ myometrium= 0.7Ϯ 0.4. The congruence between the regions was significant, with a similarity of 84% and a difference of 8% between the regions. Regression analyses of the cT 1 WI and DWI segmented treatment volumes were found to be significantly correlated ͑r 2 = 0.94, p Ͻ 0.05͒ with the linear equation, ͑cT 1 WI͒ = 1.1͑DWI͒ − 0.66. There is good agreement between the regions defined by cT1WI and DWI in most of the cases as shown from the Bland-Altman plots. Conclusions: Diffusion-weighted imaging exhibited excellent agreement, congruence, and correlation with the cT 1 WI-defined region of treatment in uterine fibroid. Therefore, DWI could be useful as an adjunct for assessing treatment of uterine fibroids by MRg-HIFUS.